Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice

References

• Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, et al. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccines Immunotherapeutics. 2015;11:1991-2004. doi:10.1080/21645515.2015.1039757
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vaccines Immunotherapeutics. 2012;8:1703-6. doi:10.4161/hv.21873
   PubMed Web of Science ®Google Scholar
• Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, Ulrich RG, Schmaljohn CS. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res. 2003;92:187-93. doi:10.1016/S0168-1702(02)00338-6. PMID:12686428
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333:850-6. doi:10.1126/science.1205669. PMID:21798894
   PubMed Web of Science ®Google Scholar
• Timmerman P, Puijk WC, Meloen RH. Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology. J Mol Recognition: JMR. 2007;20:283-99. doi:10.1002/jmr.846. PMID:18074397
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287:1664-6. doi:10.1126/science.287.5458.1664. PMID:10698744
   PubMed Web of Science ®Google Scholar
• Dube D, Brecher MB, Delos SE, Rose SC, Park EW, Schornberg KL, Kuhn JH, White JM. The primed ebolavirus glycoprotein (19-kgdalton GP1,2): sequence and residues critical for host cell binding. J Virol. 2009;83:2883-91. doi:10.1128/JVI.01956-08. PMID:19144707
   PubMed Web of Science ®Google Scholar
• Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol. 2006;80:4174-8. doi:10.1128/JVI.80.8.4174-4178.2006. PMID:16571833
   PubMed Web of Science ®Google Scholar
• Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science. 2005;308:1643-5. doi:10.1126/science.1110656. PMID:15831716
   PubMed Web of Science ®Google Scholar
• Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, et al. Emergence of Ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail. Cell Reports. 2015;12:2111-20. doi:10.1016/j.celrep.2015.08.038. PMID:26365189
   PubMed Web of Science ®Google Scholar
• Olal D, Kuehne AI, Bale S, Halfmann P, Hashiguchi T, Fusco ML, Lee JE, King LB, Kawaoka Y, Dye JM, Jr, et al. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol. 2012;86:2809-16. doi:10.1128/JVI.05549-11. PMID:22171276
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathogens. 2006;2:e1. doi:10.1371/journal.ppat.0020001. PMID:16415982
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003;362:1953-8. doi:10.1016/S0140-6736(03)15012-X. PMID:14683653
   PubMed Web of Science ®Google Scholar
• Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol. 2007;81:1821-37. doi:10.1128/JVI.02098-06. PMID:17151111
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998;246:134-44. doi:10.1006/viro.1998.9176. PMID:9657001
   PubMed Web of Science ®Google Scholar
• Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454:177-82. doi:10.1038/nature07082. PMID:18615077
   PubMed Web of Science ®Google Scholar
• Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner HL, Vu H, Shulenin S, He S, Kuehne A, et al. Cooperativity enables Non-neutralizing antibodies to neutralize Ebolavirus. Cell Reports. 2017;19:413-24. doi:10.1016/j.celrep.2017.03.049. PMID:28402862
   PubMed Web of Science ®Google Scholar
• Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2015;90:279-91. doi:10.1128/JVI.02172-15. PMID:26468532
   PubMed Web of Science ®Google Scholar
• Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Mabila M, Rucker JB, Doranz BJ. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J Virol. 2015;89:10982-92. doi:10.1128/JVI.01490-15. PMID:26311869
   PubMed Web of Science ®Google Scholar
• Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A. 2014;111:17182-7. doi:10.1073/pnas.1414164111. PMID:25404321
   PubMed Web of Science ®Google Scholar
• Tran EE, Nelson EA, Bonagiri P, Simmons JA, Shoemaker CJ, Schmaljohn CS, Kobinger GP, Zeitlin L, Subramaniam S, White JM. Mapping of Ebolavirus neutralization by monoclonal antibodies in the ZMapp cocktail using Cryo-electron tomography and studies of cellular entry. J Virol. 2016;90:7618-27. doi:10.1128/JVI.00406-16. PMID:27279622
   PubMed Web of Science ®Google Scholar
• Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE, Jr, et al. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nature Microbiol. 2016;1:16128. doi:10.1038/nmicrobiol.2016.128. PMID:27562261
   PubMed Web of Science ®Google Scholar
• Schmaljohn C, Vanderzanden L, Bray M, Custer D, Meyer B, Li D, Rossi C, Fuller D, Fuller J, Haynes J, et al. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J Virol. 1997;71:9563-9; PMID:9371620
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine. 2006;24:4490-3. doi:10.1016/j.vaccine.2005.08.014. PMID:16140436
   PubMed Web of Science ®Google Scholar
• Lee JE, Kuehne A, Abelson DM, Fusco ML, Hart MK, Saphire EO. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain. J Mol Biol. 2008;375:202-16. doi:10.1016/j.jmb.2007.10.017. PMID:18005986
   PubMed Web of Science ®Google Scholar